Literature DB >> 20015761

Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancer.

Shan-Shien Lee1, Pen-Yuan Chu.   

Abstract

We present a unique case of toxic epidermal necrolysis (TEN) caused by cetuximab plus minocycline during chemoradiation for recurrent squamous cell carcinoma of the head and neck (SCCHN). In April 2008, a 49-year-old man was diagnosed with recurrent SCCHN. He received surgery and postoperative adjuvant therapy with cetuximab plus chemoradiation. Because of exacerbation of acneform rash by cetuximab, minocycline was added thereafter. However, TEN appeared after the fifth course of weekly cetuximab, and cetuximab plus minocycline was assumed to be the cause. Cetuximab plus minocycline carries a risk of evoking TEN, and the side effects of chemoradiation for SCCHN mask some early signs of TEN. Noticing the transformation of skin lesions makes early diagnosis possible, and prompt cessation of the causative agent is essential for patients with TEN. We review the literature on cetuximab, minocycline, and TEN and discuss the impact of TEN on cancer therapy. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20015761     DOI: 10.1016/j.amjoto.2009.02.021

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  6 in total

1.  Life-threatening dermatologic adverse events in oncology.

Authors:  Alyx C Rosen; Yevgeniy Balagula; Dennis W Raisch; Vishvas Garg; Beatrice Nardone; Nicole Larsen; Jennifer Sorrell; Dennis P West; Milan J Anadkat; Mario E Lacouture
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

Review 2.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

3.  Cetuximab in refractory skin cancer treatment.

Authors:  Sini J Kalapurakal; James Malone; K Thomas Robbins; Lucinda Buescher; John Godwin; Krishna Rao
Journal:  J Cancer       Date:  2012-06-07       Impact factor: 4.207

Review 4.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

Review 5.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors:  Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal:  J Immunol Res       Date:  2018-01-17       Impact factor: 4.818

Review 6.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.